Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies

Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

(2017) C. Haioun et al.   JOURNAL OF CLINICAL ONCOLOGY

Enzastaurin in patients with follicular lymphoma: Results of a phase II study.

(2017) L. Schwartzberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas

(2011) T. L. Naylor et al.   CANCER RESEARCH

Signal Transduction Inhibitor Therapy for Lymphoma

(2011) T. E. Witzig et al.   Hematology-American Society of Hematology Education Program

The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3β

(2010) Henry Ogbomo et al.   BIOCHEMICAL PHARMACOLOGY

Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors

(2010) Toru Mukohara et al.   CANCER SCIENCE

Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines

(2010) Monica Civallero et al.   LEUKEMIA & LYMPHOMA

Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients

(2010) Sari Riihijärvi et al.   MODERN PATHOLOGY

Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis

(2010) C. A. Dumstorf et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context

(2010) W.-L. Kuo et al.   MOLECULAR CANCER THERAPEUTICS

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

Aggressive Lymphomas

(2010) Georg Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression

(2010) J. M. Irish et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rituximab inhibits B-cell receptor signaling

(2009) S. Kheirallah et al.   BLOOD

PKC  is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC  as a therapeutic target in chronic lymphocytic leukemia

(2009) C. Holler et al.   BLOOD

The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation

(2009) J.-P. Evenou et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Recruitment of PKC-βII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70

(2009) C Meyer zum Büschenfelde et al.   LEUKEMIA

Protein kinase C-betaII expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab

(2009) Kritika Chaiwatanatorn et al.   LEUKEMIA & LYMPHOMA

Molecular and cellular mechanisms of CLL: novel therapeutic approaches

(2009) Lisa Pleyer et al.   Nature Reviews Clinical Oncology

The incidence, natural history, biology, and treatment of transformed lymphomas

(2009) S. H. Bernstein et al.   Hematology-American Society of Hematology Education Program

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling

(2008) M. S. Raab et al.   BLOOD

Enzastaurin, a Protein Kinase C  Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells

(2008) K.-W. Lee et al.   CANCER RESEARCH

Involvement of protein kinase C β–extracellular signal-regulating kinase1/2/p38 mitogen-activated protein kinase–heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion

(2008) Kun Guo et al.   CANCER SCIENCE

Enzastaurin

(2008) Yi-Bin Chen et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

(2007) F. Morschhauser et al.   ANNALS OF ONCOLOGY